Missing: Symphony Allegro's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Symphony Allegro's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest Symphony Allegro News
Oct 19, 2021
The new Symphony Allegro IPTV Set Top Box was designed to industry standards by RFE as a new hardware solution for COMSovereign’s Global Telcom business unit which serves public and private telecommunication network operators. The Symphony Allegro IPTV set top box allows Communication Service Providers (“CSPs) of all types including cable and fiber, digital content owners as well as operators of large hospitality or residential facilities, to deploy a robust, feature-rich, and highly secure, streaming device to its end users instead of relying on traditional set-top control boxes. Because RFE is Android TV Operator Tier certified, it will be allowed to fully customize its IPTV solution for each provider, ensuring a “one-of-a-kind” service offering. RFE has begun initial manufacturing of 5,000 units which it expects to have available for sale to customers starting in early December. “As a specialist in the design and manufacture of unique, high-performance communications hardware, Symphony Allegro represents a new and powerful way for us further enable our large network of communications service providers to reach and engage with their customers,” said Thomas Mansfield, CEO of RFE. “Android TV Operator Tier certification is a significant achievement, providing us with an opportunity to capitalize on the tremendous growth in streaming and over-the-top media services. We are looking forward to working closely with content streaming providers and operators to develop and deploy highly customized and uniquely experiences to their subscribers.”
Symphony Allegro Frequently Asked Questions (FAQ)
When was Symphony Allegro founded?
Symphony Allegro was founded in 2006.
Where is Symphony Allegro's headquarters?
Symphony Allegro's headquarters is located at 7361 Calhoun Place, Rockville.
What is Symphony Allegro's latest funding round?
Symphony Allegro's latest funding round is Other Investors.
Who are the investors of Symphony Allegro?
Investors of Symphony Allegro include Symphony Capital and Alexza Pharmaceuticals.
Who are Symphony Allegro's competitors?
Competitors of Symphony Allegro include Zosano Pharma, CoLucid Pharmaceuticals, Alexza Pharmaceuticals, Neuraltus Pharmaceuticals, Pier Pharmaceuticals and 10 more.
Compare Symphony Allegro to Competitors
NeurAxon is discovering and developing next generation pain therapeutics focused on the inhibition of neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization. NeurAxon's lead product candidate, NXN-188, is a first-in-class, dual-action small molecule incorporating both nNOS inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.
Emagin Therapeutics develops new and improved drug entities to treat acute, chronic and cancer-related pain and delivery systems for pain management.
Relevare Pharmaceuticals, formerly CNSBio, is a specialty pharmaceutical company focused on the development of novel therapies to treat chronic and acute pain. Relevare Pharmaceuticals exciting clinical-stage pipeline is comprised of programs that combine or reposition drugs known to be active at CNS targets that modulate pain perception and transmission, and for which there is strong safety evidence in humans. In April 2010, CNSBio rebranded to Relevare Pharmaceuticals.
ThyroChek is the only available rapid test for elevated TSH approved by the FDA. It is a rapid, qualitative test for elevated TSH, thyroid stimulating hormone, a clinical indicator of hypothyroidism. Screening Devices Canada is producing products for the thyroid health market in the United States which is a market valued at $1.2B annually.
Painceptor develops peripherallyactive pharmaceuticals for the treatment and management of pain. Per the company, Painceptors researchers and industrial collaborators have advanced a series of highly selective organic molecules which will alleviate pain in a number of debilitating untreated diseases. PainCeptors therapeutics relieve pain by intercepting tissue specific pain at the source and promoting a receptive physiological environment for relief of chronic and acute pain.
Grand River Aseptic Pharmaceutical Packaging is a pharmaceutical contract manufacturing organization (CMO) supporting the rapid development of new biomedicines to the clinical stage in the State of Michigan. Grand River APP is the result of an alliance between Van Andel Institute (www.vai.org) and Grand Valley State University, and is operating as a non-profit, state- and federally funded corporation. Grand River APP's first aims to assure that therapeutics are properly distributed into dosage forms for all-important Phase I and Phase II human clinical trials. This process, Fill/Finish and Lyophilization, will be offered broadly to academic, nonprofit, and for-profit organizations in Michigan and across North America for liquid-based drug candidates that require vialing in an FDA-regulated aseptic clean room environment. Typical products envisioned for Grand River APP services include small molecule drugs, peptides, monoclonal antibodies, therapeutic proteins and nano-medicines. As a consequence, however, Grand River APP cannot process cytotoxic/genotoxic or virally-based candidates (e.g. viral vaccines).
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.